Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	52.09	75.05	93.12	203.43	288.64	181.38
Short-Term Investments	295.1	179.82	368.21	136.25	133.89	165.69
Cash & Short-Term Investments	347.19	254.87	461.33	339.68	422.53	347.07
Cash Growth	128.93%	-44.75%	35.81%	-19.61%	21.74%	-2.51%
Receivables	152.49	144.16	165.5	148.93	140.88	87.33
Inventory	68.16	77.41	91.54	85.96	48.33	26.63
Prepaid Expenses	23.17	16.68	15.78	27.02	18.68	11.61
Total Current Assets	591	493.11	734.15	601.59	630.42	472.64
Property, Plant & Equipment	40.04	42.52	44.08	52.32	58.06	38.35
Long-Term Investments	-	16.62	93.9	119.17	350.36	591.77
Goodwill	117.02	117.02	117.02	117.52	77.91	-
Other Intangible Assets	559.64	599.89	702.46	784.69	364.34	24.84
Long-Term Deferred Tax Assets	-	-	-	-	-	32.06
Other Long-Term Assets	8.12	8.51	10.9	13.87	23.02	0.62
Total Assets	1,316	1,278	1,703	1,689	1,504	1,160
Accounts Payable	4.63	1.96	10.54	9.33	6.15	10.14
Accrued Expenses	184.88	166.26	185.67	199.47	165.62	123.12
Current Portion of Long-Term Debt	-	-	407.97	7.24	5.32	3.24
Current Portion of Leases	9.68	8.33	6.79	6.48	7.52	2.83
Current Income Taxes Payable	-	-	-	-	-	2.44
Other Current Liabilities	109.46	113.64	76.99	92.86	60.5	18.82
Total Current Liabilities	308.66	290.2	687.96	315.38	245.11	160.59
Long-Term Debt	-	-	-	385.23	375.16	364.42
Long-Term Leases	30.29	33.2	36	41.3	48.81	30.44
Long-Term Deferred Tax Liabilities	11.44	24.96	49.81	85.36	35.22	-
Other Long-Term Liabilities	7.99	7.8	42.54	46.04	54.95	9.41
Total Liabilities	358.38	356.16	816.3	873.3	759.24	564.85
Common Stock	0.06	0.06	0.05	0.05	0.05	0.05
Additional Paid-In Capital	455.17	439.49	408.12	434.34	409.33	388.41
Retained Earnings	502.6	482.56	481.25	379.92	326.5	199.55
Comprehensive Income & Other	-0.37	-0.59	-3.21	1.54	8.98	7.42
Shareholders' Equity	957.45	921.52	886.2	815.85	744.86	595.43
Total Liabilities & Equity	1,316	1,278	1,703	1,689	1,504	1,160
Total Debt	39.98	41.53	450.76	440.25	436.82	400.93
Net Cash (Debt)	307.21	229.96	104.47	18.6	336.08	537.92
Net Cash Growth	109.07%	120.12%	461.74%	-94.47%	-37.52%	27.89%
Net Cash Per Share	5.61	4.14	1.69	0.34	6.26	10.00
Filing Date Shares Outstanding	55.11	54.73	54.38	53.39	52.92	52.53
Total Common Shares Outstanding	55.05	54.72	54.25	53.26	52.87	52.53
Working Capital	282.35	202.92	46.19	286.21	385.31	312.06
Book Value Per Share	17.39	16.84	16.33	15.32	14.09	11.33
Tangible Book Value	280.79	204.61	66.72	-86.36	302.61	570.59
Tangible Book Value Per Share	5.10	3.74	1.23	-1.62	5.72	10.86
Machinery	14	14.03	13.11	14.23	14.64	12.89
Construction In Progress	-	-	0.21	0.03	-	0.43
Leasehold Improvements	14.02	14.02	14.02	14.37	15.18	14.22

Source: S&P Capital IQ. Standard template. Financial Sources.